Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy
Zhe Wang, et al.
Session 604
2:00 PM – 3:30 PM
Grand Hall B
Manchester Grand Hyatt
Real-Word Early Outcomes of Second-Line Axi-Cel Therapy in Patients with R/R LBCL
Dasom (Caroline) Lee, et al.
Session 906
9:30 AM – 11:00 AM
Pacific Ballroom Salons 24-26
Marriott Marquis San Diego Marina
Real-world Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axi-cel for R/R LBCL in the US: A CIBMTR Report
Jiasheng Wang, et al.
Session 906
9:30 AM – 11:00 AM
Pacific Ballroom Salons 24-26
Marriott Marquis San Diego Marina
Predictors of Early Safety Outcomes with Axi-Cel in Patients with R/R LBCL
Christopher Sun Strouse, et al.
Session 906
12:00 PM – 1:30 PM
Grand Ballroom 2-4
Marriott Marquis San Diego Marina
Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
Tom van Meerten, et al.
Session 623
10:30 AM – 12:00 PM
Grand Ballroom 8-9
Marriott Marquis San Diego Marina
5-Year Follow-up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in Patients With R/R Indolent Non-Hodgkin Lymphoma
Sattva Neelapu, et al
Session 623
2:45 PM – 4:15 PM
Grand Ballroom 11-13
Marriott Marquis San Diego Marina
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the iMMagine-1 Trial
Ciara Louise Freeman, et al.
Session 655
4:30 PM – 6:30 PM
Pacific Ballroom Salons 24-26
Marriott Marquis San Diego Marina
Toll-Like Receptor 7/8 Pathway is a Therapeutic Target in Primary CNS Lymphoma
James Rubenstein, et al.
Session 906
4:30 PM – 6:00 PM
Grand Ballroom 11-13
Marriott Marquis San Diego Marina
Anti-CD117 Plus Anti-SIRPa or Fc-silenced Anti-CD47 Enables Hematopoietic Stem Cell Depletion and Syngeneic Engraftment Without Development of Severe Anemia
Stephen Persaud, et al.
Session 701
5:30 PM – 7:30 PM
Early MRD detection after CAR-T Associated with Poor Outcome in LBCL
Nira Krasnow, et al.
Session 702
5:30 PM – 7:30 PM
Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort
Joseph McGuirk, et al.
Session 906
5:30 PM – 7:30 PM
Mutational Landscape and Depth of Response In Patients With Acute Myeloid Leukemia (AML) Treated With Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo
Lisa Johnson, et al.
Session 618
6:00 PM – 8:00 PM
Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients With Relapsed/Refractory Large B-Cell Lymphoma
David Miklos, et al.
Session 711
6:00 PM – 8:00 PM
KITE-753: An Autologous Rapid Manufactured Anti-CD19/CD20 CAR-T Product for the Treatment of B-cell Malignancies
Jodi Murakami, et al.
Session 711
6:00 PM – 8:00 PM
The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study
Minoo Battiwalla, et al.
Session 906
6:00 PM – 8:00 PM
Effects of Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics in Pediatric Acute Myeloid Leukemia Patient Derived Xenograft Models
Sohani Sandhu, et al.
Session 604
6:00 PM – 8:00 PM
Impact of Disease Burden, CAR-T Expansion, and Mononuclear Cell Recovery on Overall Response and Duration of Response in ZUMA-3 Pivotal Study
Sabina Adhikary, et al.
Session 613
6:00 PM – 8:00 PM
Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel
Soumya Poddar, et al.
Session 622
6:00 PM – 8:00 PM
Five-Year Outcomes of Patients (Pts) With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated With Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
Michael Wang, et al.
Session 623
6:00 PM – 8:00 PM
Impact of Mutational Landscape and CD47 Levels in the Magrolimab + Azacitidine vs Placebo + Azacitidine Trial in Patients With Untreated Higher Risk Myelodysplastic Syndrome
Lisa Johnson, et al.
Session 637
6:00 PM – 8:00 PM
Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis
Rahul Banerjee, et al.
Session 653
6:00 PM – 8:00 PM
Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-month Median Follow-up
Michael Bishop, et al.
Session 704
6:00 PM – 8:00 PM
Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany
Veit Bücklein, et al.
Session 902
6:00 PM – 8:00 PM
Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) by High-Risk Features and Prior Treatments: Updated Evidence From the CIBMTR® Registry
Kistada Wudhikarn, et al.
Session 906
6:00 PM – 8:00 PM
Treatment Patterns and Outcomes in Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma: Findings from the Flatiron Database
Surbhi Sidana, et al
In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized by Overexpression of GATA3 Transcript
Soumya Poddar, et al
A United States (US) Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Compared to Odronextamab in Third Line or Later (3L+) Diffuse Large B-Cell Lymphoma
Frederick L Locke, et al
Short-term Costs Associated With Outpatient Use of Axicabtagene Ciloleucel in Second-line Relapsed/Refractory Large B-cell Lymphoma Based on ZUMA-24 Clinical Trial
Olalekan Oluwole, et al
Real-World Interim PET/CT Scan Use During Frontline (1L) Therapy and Subsequent Treatment Characteristics in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Ran Reshef, et al
You are about to leave www.GileadKiteOncology.com website and enter a website operated by a third party. Gilead and Kite are not responsible for and do not endorse or control content on this third party website.
The content on this page is intended for healthcare professionals attending ASH 2024 taking place December 7-10, 2024 in San Diego, California. This site has been designed and funded by Gilead Sciences and Kite, a Gilead company.